Transforming Treatment for
Chronic Inflammatory Diseases
PSX-514
A Patent-Pending, FDA-Designated Orphan Drug Targeting Pouchitis and Beyond
Relief for Millions Living with Chronic Inflammation
PharmassêtX is on a mission to relieve the pain and disruption caused by chronic inflammatory diseases, starting with PSX-514 — a novel small molecule drug positioned to address a significant unmet need.
First use of PSX-514
FDA Orphan drug for treating Pouchitis
7 yrs market exclusivity
PROBLEM
The Unmet Medical Need
Innovation Bottleneck
Drug development is often slow, indication-specific, and costly
65 Million
Americans suffer from autoimmune and neurodegenerative diseases
High Costs
These diseases drive healthcare costs into the hundreds of billions each year
Symptom Masking
Current treatments offer only symptomatic relief, leaving high unmet patient need
PROBLEM
The Unmet Medical Need
65 Million
Americans suffer from autoimmune and neurodegenerative diseases
Innovation Bottleneck
Drug development is often slow, indication-specific, and costly
Symptom Masking
Current treatments offer only symptomatic relief, leaving high unmet patient need
High Costs
These diseases drive healthcare costs into the hundreds of billions each year
THE ANSWER
Our Transformative
Therapeutic Solution
PSX-514
One asset, many markets
Inflammatory
Bowel Disease
Viral & Infectious Diseases
Metabolic & Cardiovascular Diseases
Neuro-
Degenerative
Diseases
Autoimmune Diseases
A High-Value Market
Ready for Disruption
$275M
Projected revenue in Year 1 (2029)
$100M+
Risk-Adjusted Net Present Value (rNPV)
U.S. Based
Supply Chain and Manufacturing
Braintrust
Founders Leadership with >75 years of healthcare pharma industry experience
Terry Minton
Chief Executive Officer
30+ years C-level experience in healthcare and life sciences industry; advanced drug through FDA; led Innovation Center team for Humana; led pharmacogenomics laboratory companies.
Tad Dryden MD PhD MSPH
Chief Medical Officer
Gastroenterologist; immunologist; Professor of Medicine and Director of the Inflammatory Bowel Disease Program at the University of Louisville School of Medicine; 30+ years of clinical experience; 100+ publications; thought leader on speakers' bureau of major pharmaceutical companies (J&J, AbbVie, Lilly, Pfizer, Takeda) targeting IBD.
David McClure PhD JD RAC
Chief Operating Officer
27+ years in pharmaceutical and life sciences industry; diverse expertise as biochemist; patent and regulatory (FDA) attorney; manufacturing; R&D.
Advisors
Include global authorities on drug patents, clinical trial design, advanced pharmaceutical manufacturing methods, and IBD/pouchitis.